Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Crinetics Pharmaceuticals Inc operates as a clinical stage pharmaceutical company. The Company develops therapeutics for the treatment of endocrine diseases and cancers. Crinetics Pharmaceuticals serves clients in the State of California.
Website: crinetics.com



Growth: Bad revenue growth rate 0.0%, there is slowdown compared to average historical growth rates 52.8%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -8 740.0%. Gross margin is low, -88.7%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 4.7% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 232.4% higher than minimum and 0.0% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -422.2x by EV / Sales multiple

Insiders: For the last 3 months insiders sold company shares on $0.1 mln (-0.006% of cap.)

Key Financials (Download financials)

Ticker: CRNX
Share price, USD:  (0.0%)84.95
year average price 54.96  


year start price 45.91 2025-09-27

min close price 32.61 2026-06-02

max close price 84.95 2026-08-31

current price 84.95 2026-09-26
Common stocks: 53 505 799

Dividend Yield:  0.0%
EV / Sales: 859.3x
Margin (EBITDA LTM / Revenue): -8 740.0%
Fundamental value created in LTM:
Market Cap ($m): 4 545
Net Debt ($m): -249
EV (Enterprise Value): 4 296
Price to Book: 4.2x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-26globenewswire.com

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

2026-01-04globenewswire.com

Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia

2025-11-27fool.com

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year

2025-11-07seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2025 Earnings Call Transcript

2025-09-28fool.com

Is Crinetics Pharmaceuticals Stock a Buy?

2025-09-26seekingalpha.com

Crinetics: FDA Approval And Expansion Of Palsonify In Focus, Maintaining 'Buy' Rating

2025-09-26seekingalpha.com

Crinetics Pharmaceuticals, Inc. - Special Call

2025-09-25globenewswire.com

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

2025-08-09seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Q2 2025 Earnings Call Transcript

2025-05-10seekingalpha.com

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-09 2022-11-14
acceptedDate 2025-11-06 16:25:14 2025-08-07 16:39:31 2025-02-27 16:13:14 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12 2022-03-30 16:12:51 2021-03-30 17:12:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 143 000 1M 1M 0 399 000 640 000 4M 346 000 988 000 3M 5M 458 000 1M 71 000
costOfRevenue 0 0 0 0 753 000 474 000 0 273 000 398 000 0 0 0 0 57M
grossProfit 143 000 1M 1M 0 -354 000 166 000 4M 73 000 590 000 3M 5M 458 000 1M -57M
grossProfitRatio 1 1 0 -0.887 0.259 0.211 0.597 1 1
researchAndDevelopmentExpenses 90M 80M 240M 62M 58M 53M 169M 44M 41M 38M 130M 32M 84M 58M
generalAndAdministrativeExpenses 52M 50M 100M 26M 25M 21M 58M 15M 13M 12M 42M 12M 25M 18M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 52M 50M 100M 26M 25M 21M 58M 15M 13M 12M 42M 12M 25M 18M
otherExpenses 0 0 0 0 0 -251 000 0 3M -91 000 2M 0 0 0 -58M
operatingExpenses 143M 130M 340M 88M 83M 74M 227M 59M 54M 51M 173M 44M 109M 18M
costAndExpenses 143M 130M 340M 88M 83M 74M 227M 59M 54M 51M 173M 44M 109M 75M
interestIncome 13M 13M 41M 11M 9M 7M 13M 3M 2M 2M 4M 2M 157 000 991 000
interestExpense 0 0 0 0 0 0 0 0 0 -2M 0 2M 0 0
depreciationAndAmortization 1M 959 000 3M 770 000 753 000 474 000 1M 273 000 280 000 283 000 983 000 248 000 922 000 948 000
ebitda -142M -128M -336M -87M -82M -74M -222M -59M -53M -48M -167M -43M -107M -74M
ebitdaratio -990.028 -124.3 0 -205.589 -115.148 -170.454 -53.355 -17.909 -94.336
operatingIncome -143M -129M -339M -88M -83M -74M -223M -59M -53M -48M -168M -43M -108M -75M
operatingIncomeRatio -997.105 -125.23 0 -207.476 -115.889 -170.454 -53.639 -17.909 -94.878
totalOtherIncomeExpensesNet 12M 13M 40M 11M 9M 7M 8M 2M -91 000 2M 4M 2M 61 000 1M
incomeBeforeTax -130M -116M -298M -77M -74M -67M -215M -57M -51M -46M -164M -42M -108M -74M
incomeBeforeTaxRatio -909.727 -112.16 0 -185.602 -104.578 -166.064 -51.598 -17.169 -91.539
incomeTaxExpense 0 0 0 0 0 -1 0 -273 000 -2M -2M 0 -2M 0 0
netIncome -130M -116M -298M -77M -74M -67M -215M -57M -51M -44M -164M -40M -108M -74M
netIncomeRatio -909.727 -112.16 0 -185.602 -104.578 -166.064 -51.598 -16.429 -88.201
eps -1.38 -1.23 -3.69 -0.96 -0.94 -0.93 -3.69 -1.01 -0.94 -0.82 -3.15 -0.75 -2.8 -2.42
epsdiluted -1.38 -1.23 -0.96 -0.94 -0.93 -1.01 -0.94 -0.82 -0.75
weightedAverageShsOut 94M 94M 81M 80M 79M 72M 58M 57M 54M 54M 52M 54M 38M 30M
weightedAverageShsOutDil 94M 94M 81M 80M 79M 72M 58M 57M 54M 54M 52M 54M 38M 30M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2023-12-31 2023-02-28 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 41M 13M 4M 157 000 991 000
ebit -339M -223M -168M -108M -75M
nonOperatingIncomeExcludingInterest 0 0 0 0 0
netIncomeFromContinuingOperations -298M -215M -164M -108M -74M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -298M -215M -164M -108M -74M
epsDiluted -3.69 -3.69 -3.15 -2.8 -2.42

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-09 2022-11-14
acceptedDate 2025-11-06 16:25:14 2025-08-07 16:39:31 2025-02-27 16:13:14 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12 2022-03-30 16:12:51 2021-03-30 17:12:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 111M 54M 265M 317M 302M 396M 55M 143M 40M 41M 33M 31M 201M 93M
shortTermInvestments 981M 1 143M 1 090M 545M 561M 505M 504M 412M 225M 255M 302M 337M 133M 78M
cashAndShortTermInvestments 1 092M 1 196M 1 354M 863M 863M 901M 559M 555M 265M 296M 334M 368M 334M 171M
netReceivables 0 0 8M 7M 5M 9M 9M 12M 2M 2M 2M 2M 2M 2M
inventory 0 0 0 0 0 0 0 -12M 15M -2M 0 0 0 0
otherCurrentAssets 29M 21M 2M 8M 7M 7M 2M 21M 3M 9M 3M 2M 0 1M
totalCurrentAssets 1 121M 1 217M 1 375M 878M 875M 917M 574M 576M 285M 305M 345M 378M 345M 177M
propertyPlantEquipmentNet 56M 57M 56M 56M 57M 58M 57M 58M 4M 5M 5M 5M 5M 5M
goodwill 0 0 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 800 000 800 000 0 2M 1M 2M 6M 2M 0 2M 0 1M 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 19M 15M 3M 4M 2M 2M 2M 2M 2M 4M 36 999 1M 568 000 540 000
totalNonCurrentAssets 75M 72M 59M 60M 61M 61M 61M 66M 8M 9M 7M 7M 6M 6M
otherAssets 0 0 0 0 0 0 0 0 1000 0 0 0 0 0
totalAssets 1 196M 1 290M 1 435M 937M 936M 978M 635M 642M 293M 314M 352M 385M 351M 183M
accountPayables 6M 11M 6M 5M 9M 11M 7M 6M 5M 6M 7M 6M 3M 3M
shortTermDebt 6M 7M 0 7M 15M 6M 4M 4M 1M 1M 1M 1M 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 2M 2M 2M 3M 2M 2M 2M 2M 2M 2M 2M 0 0
otherCurrentLiabilities 62M 49M 10000 40M 28M 33M 17M 29M 25M 17M 8M 15M 8M 5M
totalCurrentLiabilities 74M 68M 60M 54M 54M 52M 44M 40M 33M 26M 28M 25M 16M 10M
longTermDebt 43M 43M 0 45M 46M 47M 0 48M 1M 2M 0 2M 0 0
deferredRevenueNonCurrent 0 4M 5M 0 4M 5M 5M 5M 5M 6M 6M 7M 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 -5M 0 0 0 0 0 0
otherNonCurrentLiabilities 7M 2M 829 000 6M 202 000 -1 0 5M 0 0 0 -267 000 2000 23 000
totalNonCurrentLiabilities 50M 50M 50M 51M 50M 51M 52M 53M 7M 7M 8M 9M 3M 4M
otherLiabilities 0 0 0 0 0 1 0 0 0 0 0 0 0 0
capitalLeaseObligations 49M 50M 52M 53M 53M 47M 48M 52M 3M 3M 2M 3M 3M 4M
totalLiabilities 124M 118M 110M 104M 105M 103M 96M 94M 39M 34M 36M 34M 19M 15M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 2 365M 2 335M 2 276M 1 702M 1 626M 1 595M 1 192M 1 142M 792M 768M 759M 751M 608M 337M
retainedEarnings -1 295M -1 165M -952M -872M -795M -721M -654M -594M -536M -485M -439M -394M -275M -168M
accumulatedOtherComprehensiveIncomeLoss 2M 2M 963 000 2M -190 000 150 000 977 000 -865 000 -2M -3M -4M -5M -382 000 25 000
othertotalStockholdersEquity 0 -112 000 0 0 0 -1 141M 0 -765M 0
totalStockholdersEquity 1 072M 1 172M 1 325M 833M 831M 875M 539M -594M 254M -485M 316M 351M 332M 169M
totalEquity 1 072M 1 172M 1 325M 833M 831M 875M 539M -594M 254M -485M 316M 351M 332M 169M
totalLiabilitiesAndStockholdersEquity 1 196M 1 290M 937M 936M 978M -500M 293M -451M 385M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 196M 1 290M 1 435M 937M 936M 978M 635M -500M 293M -451M 352M 385M 351M 183M
totalInvestments 981M 1 143M 1 090M 545M 562M 506M 505M 412M 225M 255M 304M 337M 134M 78M
totalDebt 49M 50M 52M 53M 53M 53M 52M 52M 3M 3M 3M 3M 3M 4M
netDebt -62M -4M -213M -265M -249M -343M -3M -91M -37M -38M -30M -28M -198M -89M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2023-12-31 2023-02-28 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 0 0 0 2M
otherReceivables 8M 9M 2M 0 2M
prepaids 11M 5M 6M 9M 4M
totalPayables 6M 7M 7M 3M 3M
otherPayables 0 0 0 0 0
accruedExpenses 44M 15M 9M 5M 2M
capitalLeaseObligationsCurrent 7M 0 0 0 0
capitalLeaseObligationsNonCurrent 45M 48M 2M 3M 4M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 0 0 0 0 0
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-12 2024-08-08 2024-05-09 2023-11-07 2023-08-08 2023-05-09 2022-11-14
acceptedDate 2025-11-06 16:25:14 2025-08-07 16:39:31 2025-02-27 16:13:14 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12 2022-03-30 16:12:51 2021-03-30 17:12:59
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -130M -116M -298M -77M -74M -67M -215M -57M -51M -46M -164M -42M -108M -74M
depreciationAndAmortization 1M 959 000 3M 770 000 753 000 474 000 1M 273 000 280 000 283 000 983 000 248 000 922 000 948 000
deferredIncomeTax 0 0 0 0 0 0 0 -7M -905 000 0 0 0 422 000 -227 000
stockBasedCompensation 23M 26M 69M 18M 19M 13M 41M 11M 10M 8M 28M 7M 17M 10M
changeInWorkingCapital -1M 7M 12M -14M 11M 3M 8M 5M -4M -687 000 19M -4M 1M 376 000
accountsReceivables 0 0 18M 0 0 0 15M 0 0 0 11M 0 6M 3M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 -6M -3M
accountsPayables 7M 13M 0 0 7M 1M 0 4M 7M -1M 0 0 6M 3M
otherWorkingCapital -8M -6M -6M -14M 4M 1M -7M 470 000 -12M 658 000 8M -4M -5M -2M
otherNonCashItems -3M -4M -11M 9M -3M 11M -2M 7M 118 000 -2M 850 000 -29 000 -739 000 261 000
netCashProvidedByOperatingActivities -111M -86M -226M -63M -46M -53M -166M -41M -46M -41M -115M -38M -89M -62M
investmentsInPropertyPlantAndEquipment -863 000 -3M -4M -528 000 -955 000 -1M -5M -4M -237 000 -16 000 -2M -682 000 -436 000 -186 000
acquisitionsNet 0 0 0 0 0 0 0 190M -32M -530 000 0 0 422 000 -227 000
purchasesOfInvestments -217M -183M -1 147M -141M -192M -100M -533M -278M -59M -23M -330M -49M -125M -136M
salesMaturitiesOfInvestments 382M 224M 576M 151M 139M 101M 337M 88M 91M 71M 157M 56M 69M 136M
otherInvestingActivites 0 0 11M 0 2M -190M 32M 530 000 0
netCashUsedForInvestingActivites 165M 38M 21M -54M 309 000 -193M 31M 49M 7M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 3M 7M 47M -4M 394M 338M 13M 484 000 -13 000
commonStockRepurchased 0 0 0 0 0 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 0 0 11M 5M 394M 338M 0 0 1M
netCashUsedProvidedByFinancingActivities 3M 7M 57M 5M 394M 338M 13M 484 000 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 0 0 0 0 0
netChangeInCash 57M -41M 210M 16M -94M 341M 22M 103M -2M 9M -167M -31M 108M 53M
cashAtEndOfPeriod 111M 54M 266M 319M 302M 396M 56M 143M 41M 42M 34M 32M 201M 94M
cashAtBeginningOfPeriod 54M 95M 56M 302M 396M 55M 34M 40M 42M 34M 201M 63M 94M 41M
operatingCashFlow -111M -86M -226M -63M -46M -53M -166M -41M -46M -41M -115M -38M -89M -62M
capitalExpenditure -863 000 -3M -4M -528 000 -955 000 -1M -5M -4M -237 000 -16 000 -2M -682 000 -436 000 -186 000
freeCashFlow -112M -89M -230M -63M -47M -54M -171M -45M -46M -41M -117M -39M -89M -62M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-27 2023-12-31 2023-02-28 2022-03-30 2021-03-30
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -422 000 227 000
netCashProvidedByInvestingActivities -575M -200M -174M -56M 217 000
netDebtIssuance 0 0 0 0 0
longTermNetDebtIssuance 0 0 0 0 0
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 970M 369M 117M 250M 114M
netCommonStockIssuance 970M 369M 117M 250M 114M
commonStockIssuance 970M 369M 117M 250M 114M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 40M 20M 5M 3M 288 000
netCashProvidedByFinancingActivities 1 010M 389M 122M 253M 115M
incomeTaxesPaid 0 0 0 0 0
interestPaid 0 0 0 0 0

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-11 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)

Press-releases

Show financial reports only

2026-08-03 ET
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-06 ET
Vertex to Acquire Crinetics Pharmaceuticals
2026-06-30 ET
Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026
2026-06-14 ET
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
2026-06-14 ET
Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026
2026-06-14 ET
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
2026-06-14 ET
Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control
2026-06-02 ET
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
2026-06-02 ET
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
2026-06-02 ET
Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations
2026-05-22 ET
Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026
2026-05-07 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
2026-04-27 21:13 ET
Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Acromegaly in Adults
2026-04-08 ET
Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
2026-03-26 ET
Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusotine) in Acromegaly
2026-02-26 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2026-02-05 21:05 ET
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March
2026-01-26 ET
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
2026-01-22 ET
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2026-01-22 ET
Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2026-01-12 ET
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-01-06 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2026-01-05 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2026-01-05 ET
Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia
2026-01-04 ET
Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia
2025-12-19 ET
Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
2025-12-18 ET
Crinetics Pharmaceuticals to Participate in The 44th Annual J.P. Morgan Healthcare Conference
2025-12-11 ET
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2025-12-11 ET
Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2025-12-10 ET
Crinetics Pharmaceuticals Announces December 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-12-03 ET
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
2025-12-03 ET
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
2025-11-20 ET
Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome
2025-11-10 ET
Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-11-06 21:05 ET
Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
2025-10-23 ET
Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting
2025-10-10 ET
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-10-06 ET
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
2025-09-25 ET
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
2025-09-25 ET
Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly
2025-09-10 ET
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-21 ET
Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)
2025-08-11 ET
Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-08-07 ET
Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
2025-07-13 ET
Crinetics to Present New Long-Term Data Demonstrating Durable Control of Once-Daily, Oral PALSONIFY™ (Paltusotine) in Acromegaly at ENDO 2025
2025-07-11 ET
Crinetics Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025
2025-07-10 ET
Crinetics Pharmaceuticals Announces July 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-30 ET
Crinetics to Showcase the Next Generation of Endocrinology Innovation at ENDO 2025 with Eight Presentations From its Deep Pipeline
2025-06-16 ET
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
2025-06-10 ET
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-23 ET
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
2025-05-15 ET
Crinetics to Present New Research on Paltusotine, Atumelnant and Unmet Needs in Acromegaly Treatment at the American Association of Clinical Endocrinology Annual Meeting 2025
2025-05-12 ET
Crinetics Pharmaceuticals Announces May 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-05-08 ET
Crinetics Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
2025-04-11 ET
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
2025-04-10 ET
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-27 ET
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
2025-03-10 ET
Crinetics Pharmaceuticals Announces March 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-27 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
2025-02-24 ET
Crinetics Pharmaceuticals Appoints Tobin Schilke as Chief Financial Officer
2025-02-20 ET
Crinetics Pharmaceuticals to Participate in Two Upcoming March Investor Conferences
2025-02-10 ET
Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-02-06 ET
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
2025-01-10 ET
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-01-10 ET
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
2025-01-06 ET
Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
2024-12-16 ET
Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer
2024-12-10 ET
Crinetics Pharmaceuticals Announces December 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-12-09 ET
Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
2024-11-15 ET
Crinetics Pharmaceuticals to Participate in Three Upcoming December Investor Conferences
2024-11-12 21:07 ET
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
2024-11-12 21:05 ET
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-11 21:05 ET
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-16 12:00 ET
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
2024-10-10 20:40 ET
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-09 03:55 ET
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2024-10-08 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2024-09-26 20:05 ET
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
2024-09-10 20:40 ET
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 20:05 ET
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2024-08-12 20:05 ET
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 20:05 ET
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-08 12:30 ET
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
2024-07-18 20:05 ET
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-07-10 23:29 ET
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-18 20:30 ET
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
2024-06-10 22:35 ET
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-03 16:00 ET
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
2024-06-03 16:00 ET
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
2024-05-30 20:05 ET
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
2024-05-22 12:00 ET
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
2024-05-10 21:38 ET
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-09 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-08 20:05 ET
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
2024-05-02 20:05 ET
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
2024-04-11 20:05 ET
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 10:00 ET
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
2024-03-12 20:05 ET
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
2024-03-11 20:05 ET
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-28 21:05 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-28 13:00 ET
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
2024-02-28 13:00 ET
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
2024-02-14 21:05 ET
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
2024-02-12 21:05 ET
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-10 21:33 ET
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 13:00 ET
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 12:00 ET
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
2024-01-03 ET
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
2023-12-18 21:05 ET
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
2023-12-11 21:05 ET
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-20 21:05 ET
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-11-10 22:00 ET
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 21:05 ET
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-17 14:15 ET
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
2023-10-10 21:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-20 12:00 ET
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
2023-09-13 02:26 ET
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2023-09-11 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-09-11 10:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-10 14:00 ET
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
2023-08-10 21:34 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-08 11:00 ET
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-31 12:01 ET
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
2023-07-10 20:18 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-21 11:59 ET
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
2023-06-12 11:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-09 11:30 ET
Crinetics to Highlight Broad Pipeline at ENDO 2023
2023-05-10 20:21 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-04-10 20:31 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-10 21:37 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-28 21:05 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-02-10 22:21 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-10 13:01 ET
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
2023-01-10 21:48 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-09 13:01 ET
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 21:01 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-28 13:00 ET
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
2022-11-22 13:00 ET
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-11-14 13:00 ET
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-10 21:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-13 12:00 ET
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
2022-10-10 20:57 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-06 12:00 ET
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
2022-10-03 12:00 ET
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
2022-09-12 12:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-08 12:00 ET
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-09-06 12:00 ET
New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
2022-09-02 12:00 ET
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
2022-08-12 12:00 ET
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-08-10 20:44 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-04 12:00 ET
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
2022-07-12 21:09 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-10 20:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-08 11:30 ET
Crinetics Presents Clinical and Research Results at ENDO 2022
2022-06-07 11:30 ET
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
2022-05-25 11:00 ET
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
2022-05-12 20:41 ET
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-10 20:18 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-18 20:01 ET
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
2022-04-13 03:50 ET
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
2022-04-11 21:15 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-30 20:02 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-30 20:01 ET
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
2022-03-21 11:30 ET
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
2022-03-14 11:30 ET
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
2022-03-10 22:20 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-01 13:00 ET
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
2022-02-28 11:00 ET
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
2022-02-09 12:30 ET
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
2022-02-01 21:42 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-12 12:30 ET
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
2022-01-05 12:30 ET
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
2021-11-18 13:00 ET
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-08 13:00 ET
Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
2021-11-05 12:00 ET
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-10-25 20:01 ET
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-10-21 12:22 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-10-20 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2021-10-18 20:00 ET
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
2021-09-27 11:30 ET
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
2021-09-15 20:01 ET
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
2021-09-07 11:30 ET
Crinetics Pharmaceuticals to Participate in September Investor Conferences
2021-09-02 11:30 ET
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
2021-08-10 20:02 ET
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-10 20:01 ET
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
2021-07-29 11:30 ET
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
2021-06-28 11:30 ET
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
2021-06-16 12:30 ET
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
2021-05-06 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-04-12 20:05 ET
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
2021-04-07 22:31 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-03-30 20:05 ET
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-24 11:10 ET
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
2021-03-22 11:10 ET
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
2021-03-12 12:10 ET
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
2021-02-04 12:10 ET
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
2021-02-03 12:10 ET
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
2021-01-06 12:05 ET
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 
2020-11-23 12:30 ET
Crinetics Pharmaceuticals to Participate in December Investor Conferences
2020-11-16 12:30 ET
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
2020-11-13 12:30 ET
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
2020-11-06 13:31 ET
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-10-26 11:02 ET
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
2020-09-21 11:30 ET
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
2020-09-04 11:30 ET
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
2020-09-03 21:56 ET
Crinetics Pharmaceuticals to Participate in September Investor Conferences
2020-09-03 11:30 ET
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
2020-08-07 11:30 ET
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-08 20:05 ET
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
2020-06-11 11:30 ET
Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
2020-05-27 11:30 ET
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
2020-05-08 13:01 ET
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-04-17 20:05 ET
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-04-15 04:21 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-04-14 20:05 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-04-06 20:30 ET
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
2020-03-09 20:10 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-02-19 12:30 ET
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
2020-01-08 12:30 ET
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
2019-11-26 21:05 ET
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
2019-11-12 21:04 ET
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-09-25 11:30 ET
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 10
2026-08-03 20:13 ET
Crinetics Pharmaceuticals reported for 2026 q2
SEC form 8
2026-08-03 20:09 ET
Crinetics Pharmaceuticals published news for 2026 q2
SEC form 8
2026-08-03 20:09 ET
Crinetics Pharmaceuticals reported for 2026 q2
SEC form 8
2026-07-06 21:17 ET
Crinetics Pharmaceuticals published news for 2026 q2
SEC form 8
2026-07-06 21:17 ET
Crinetics Pharmaceuticals published news for 2026 q2
SEC form 8
2026-07-06 21:17 ET
Crinetics Pharmaceuticals published news for 2026 q2
SEC form 10
2026-05-07 20:21 ET
Crinetics Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 20:16 ET
Crinetics Pharmaceuticals published news for 2026 q1
SEC form 8
2026-05-07 20:16 ET
Crinetics Pharmaceuticals reported for 2026 q1
SEC form 8
2026-03-03 21:07 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-03-03 21:07 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 10
2026-02-26 16:25 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-26 16:15 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-02-26 16:15 ET
Crinetics Pharmaceuticals reported for 2025 q4
SEC form 8
2026-01-13 22:02 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-13 22:02 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-07 21:39 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-07 21:39 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-07 21:39 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-07 21:39 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-07 21:39 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-05 21:01 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-05 21:01 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 8
2026-01-05 21:01 ET
Crinetics Pharmaceuticals published news for 2025 q4
SEC form 10
2025-11-06 21:25 ET
Crinetics Pharmaceuticals reported for 2025 q3
SEC form 8
2025-11-06 21:20 ET
Crinetics Pharmaceuticals published news for 2025 q3
SEC form 8
2025-11-06 21:20 ET
Crinetics Pharmaceuticals reported for 2025 q3
SEC form 8
2025-09-25 17:36 ET
Crinetics Pharmaceuticals published news for 2025 q2
SEC form 8
2025-09-25 17:36 ET
Crinetics Pharmaceuticals published news for 2025 q2
SEC form 10
2025-08-07 20:39 ET
Crinetics Pharmaceuticals reported for 2025 q2
SEC form 8
2025-08-07 20:38 ET
Crinetics Pharmaceuticals published news for 2025 q2
SEC form 8
2025-08-07 20:38 ET
Crinetics Pharmaceuticals reported for 2025 q2
SEC form 8
2025-06-30 20:26 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-30 20:26 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-26 20:16 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-26 20:16 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-08 20:14 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-08 20:09 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 20:09 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-27 16:13 ET
Crinetics Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-12 16:15 ET
Crinetics Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-12 16:08 ET
Crinetics Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-12 16:08 ET
Crinetics Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-08 16:13 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Crinetics Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-28 16:15 ET
Crinetics Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-28 16:09 ET
Crinetics Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:09 ET
Crinetics Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-07 16:11 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-07 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-08 07:07 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-08 07:01 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 6
2023-06-21 16:36 ET
Crinetics Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-13 08:30 ET
Crinetics Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 16:26 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-28 16:13 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:43 ET
Crinetics Pharmaceuticals published news for 2022 q4
SEC form 6
2022-11-28 08:32 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-14 08:31 ET
Crinetics Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-14 08:15 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-13 08:32 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 08:30 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-14 18:08 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-12 08:46 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-12 08:41 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-12 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-12 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-21 16:31 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-25 07:02 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 16:49 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-12 16:40 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-28 16:50 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-13 16:26 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-03-30 16:12 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-30 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-25 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-17 18:22 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-14 09:01 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 08:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 08:30 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-12 07:35 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-05 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-23 16:30 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-08 08:53 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 08:02 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-05 08:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-05 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-21 16:24 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-20 16:19 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 8
2021-10-20 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-18 16:08 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-27 07:54 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-15 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-02 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-02 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-10 16:09 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-10 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:15 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-28 07:30 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-23 16:55 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:01 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 16:01 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 18:16 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-08 16:09 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-30 17:12 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-30 17:05 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-04 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 10
2020-11-06 08:33 ET
Crinetics Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-06 08:30 ET
Crinetics Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-26 06:55 ET
Crinetics Pharmaceuticals published news for 2020 q3